Effectiveness and adherence in a tirzepatide-supported digital weight-loss programme in Australia: A real-world observational study.

Talay L, Hom J, Scott T, Ahuja N

Diabetes, obesity & metabolism14 Jan 2026Cited by 2 (Europe PMC)

PMID41532325PMCIDPMC12992185DOI10.1111/dom.70462PepBankPUB-41532325

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study10

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone10

In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Tirzepatide.

01HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome
In adults in a tirzepatide-supported digital weight-loss programme, 31.7% met adherence criteria at 6 months.
In plain wordsIn a digital weight-loss programme that included tirzepatide, 31.7% of people met the adherence criteria at 6 months.
Peptide
Tirzepatide
Outcome
Not applicableAdherence at 6 months
Study
n = 4,309
Analysis
Primary
Outcome group
Treatment adherence and retention · Whole body
Measurements
Adherence
31.7%
6 months
Source sentences
Summary
At 6 months, 31.7% met adherence criteria
1 context sentence(design, population, supporting numbers)
Summary · context
All patients initiating tirzepatide through the Juniper AU DWLS between 1 September 2024 and 23 April 2025 (n = 4309) were analysed.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4153232501
02HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome
In adults in a tirzepatide-supported digital weight-loss programme, 16.1% were adherent at 12 months.
In plain wordsIn a digital weight-loss programme that included tirzepatide, 16.1% of people were adherent at 12 months.
Peptide
Tirzepatide
Outcome
Not applicableAdherence at 12 months
Study
n = 4,309
Analysis
Primary
Outcome group
Treatment adherence and retention · Whole body
Measurements
Adherence
16.1%
12 months
Source sentences
Summary
At 12 months, 16.1% were adherent
1 context sentence(design, population, supporting numbers)
Summary · context
All patients initiating tirzepatide through the Juniper AU DWLS between 1 September 2024 and 23 April 2025 (n = 4309) were analysed.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4153232502
03HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome
In adherent adults in a tirzepatide-supported digital programme, mean weight loss was 16.9% at 6 months.
In plain wordsIn people who stuck with a digital programme that included tirzepatide, average weight loss was 16.9% at 6 months.
Peptide
Tirzepatide
Outcome
DecreaseMean weight loss at 6 months among adherent patients
Study
n: not reported in source
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Measurements
Mean weight loss
16.9%
6 months, adherent patients
Source sentences
Summary
mean weight loss among adherent patients was 16.9% (±8.6; 95% CI 16.6-17.2)
1 context sentence(design, population, supporting numbers)
Summary · context
All patients initiating tirzepatide through the Juniper AU DWLS between 1 September 2024 and 23 April 2025 (n = 4309) were analysed.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4153232503
04HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome
In adherent adults in a tirzepatide-supported digital programme, mean weight loss was 22.7% at 12 months.
In plain wordsIn people who stuck with a digital programme that included tirzepatide, average weight loss was 22.7% at 12 months.
Peptide
Tirzepatide
Outcome
DecreaseMean weight loss at 12 months among adherent patients
Study
n: not reported in source
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Measurements
Mean weight loss
22.7%
12 months, adherent patients
Source sentences
Summary
mean weight loss was 22.7%
1 context sentence(design, population, supporting numbers)
Summary · context
All patients initiating tirzepatide through the Juniper AU DWLS between 1 September 2024 and 23 April 2025 (n = 4309) were analysed.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4153232505
05HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome
In adherent adults in a tirzepatide-supported digital programme, 98.0% achieved at least 5% weight reduction at 6 months.
In plain wordsIn people who stuck with a digital programme that included tirzepatide, 98.0% lost at least 5% of body weight at 6 months.
Peptide
Tirzepatide
Outcome
DecreaseProportion with at least 5% weight loss at 6 months
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Measurements
Responders with ≥5% weight loss
98%
6 months, adherent patients
Source sentences
Summary
with 98.0% achieving ≥5% weight reductions.
1 context sentence(design, population, supporting numbers)
Summary · context
All patients initiating tirzepatide through the Juniper AU DWLS between 1 September 2024 and 23 April 2025 (n = 4309) were analysed.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4153232504
06HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome
In adherent adults in a tirzepatide-supported digital programme, 100% reached at least 5% weight loss at 12 months.
In plain wordsIn people who stuck with a digital programme that included tirzepatide, all reached at least 5% weight loss at 12 months.
Peptide
Tirzepatide
Outcome
DecreaseProportion with at least 5% weight loss at 12 months
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Measurements
Responders with ≥5% weight loss
100%
12 months, adherent patients
Source sentences
Summary
and 100% of patients reached the ≥5% milestone.
1 context sentence(design, population, supporting numbers)
Summary · context
All patients initiating tirzepatide through the Juniper AU DWLS between 1 September 2024 and 23 April 2025 (n = 4309) were analysed.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4153232506
07HumanNot a test of Tirzepatide aloneObservational studyOther
In a tirzepatide-supported digital programme, 1-month weight loss was the strongest predictor of 6- and 12-month outcomes.
In plain wordsIn a digital programme that included tirzepatide, early weight loss in month one was linked to better results at 6 and 12 months.
Peptide
Tirzepatide
Outcome
Not applicablePredictors of 6- and 12-month outcomes
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
Multivariable models identified 1-month weight loss as the strongest predictor of 6- and 12-month outcomes
1 context sentence(design, population, supporting numbers)
Summary · context
All patients initiating tirzepatide through the Juniper AU DWLS between 1 September 2024 and 23 April 2025 (n = 4309) were analysed.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4153232507
08HumanNot a test of Tirzepatide aloneObservational studyOther
In a tirzepatide-supported digital programme, sustained weekly weight tracking and health coach messaging were strongly associated with retention and greater weight loss.
In plain wordsIn a digital programme that included tirzepatide, regular weight tracking and coach messages were linked to staying in the programme and losing more weight.
Peptide
Tirzepatide
Outcome
Not applicableWeight tracking and coach messaging with retention and weight loss
Study
n: not reported in source
Outcome group
Treatment adherence and retention · Whole body
Source sentences
Summary
sustained weekly weight tracking and health coach messaging were strongly associated with both retention and greater weight loss.
1 context sentence(design, population, supporting numbers)
Summary · context
All patients initiating tirzepatide through the Juniper AU DWLS between 1 September 2024 and 23 April 2025 (n = 4309) were analysed.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4153232508
09HumanNot a test of Tirzepatide aloneObservational studyOther
In a tirzepatide-supported digital programme, very frequent weight tracking in month one correlated with poorer outcomes and reduced retention.
In plain wordsIn a digital programme that included tirzepatide, very frequent weight checks in month one were linked to poorer results and less retention.
Peptide
Tirzepatide
Outcome
Not applicableVery frequent weight tracking in month one
Study
n: not reported in source
Outcome group
Treatment adherence and retention · Whole body
Source sentences
Summary
Paradoxically, very frequent weight tracking in month one correlated with poorer outcomes and reduced retention.
1 context sentence(design, population, supporting numbers)
Summary · context
All patients initiating tirzepatide through the Juniper AU DWLS between 1 September 2024 and 23 April 2025 (n = 4309) were analysed.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4153232509
10HumanNot a test of Tirzepatide aloneObservational studySafety outcome
In a tirzepatide-supported digital programme, side effects were common but mostly mild or moderate and did not correlate with weight loss or retention.
In plain wordsIn a digital programme that included tirzepatide, side effects were common but mostly mild or moderate, and not linked to weight loss or retention.
Peptide
Tirzepatide
Outcome
Not applicableSide effects
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Source sentences
Summary
Side effects were common but mostly mild/moderate and did not correlate with weight loss or programme retention.
1 context sentence(design, population, supporting numbers)
Summary · context
All patients initiating tirzepatide through the Juniper AU DWLS between 1 September 2024 and 23 April 2025 (n = 4309) were analysed.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4153232510

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:07 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.